The pivotal phase 3 GRAVITAS-301 study – designed to evaluate itacitinib in combination with corticosteroids in patients with treatment-naïve acute graft-versus-host disease – failed to meet its primary endpoint of improving overall response rates.
However, the recent addition of new chemotherapy-free options such as chimeric antigen receptor (CAR)-T cell therapy could offer hope for patients with mantle cell lymphoma who develop resistance to chemotherapy-based treatment.
While chemotherapy is widely used in the frontline treatment of mantle cell lymphoma (MCL), earlier use of BTK inhibitors such as Imbruvica (ibrutinib) may soon make chemotherapy obsolete for some patients, according to new data presented at the 2019 American Society of Hematology (ASH) Annual Meeting.
While resistance can often make it a challenge to treat mantle cell lymphoma, therapies have come a long way in recent years thanks to the emergence of personalized treatment and the use of BTK inhibitors, according to one expert.
Researchers are expanding a clinical trial to include more patients with mantle cell lymphoma after some patients given the combination of medications under investigation showed no signs of cancer after treatment.